A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the safety and effect of ATN-224 in combination with
bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory
to bortezomib.